UNITED STATES



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  October 15, 2007


COMPUMED, INC.

(Exact name of registrant as specified in its charter)



DELAWARE

 

000-14210

 

95-2860434

(State or other jurisdiction of incorporation)

 

(Commission  File Number)

 

(IRS Employer Identification No.)



5777 West Century Blvd., Suite 1285, Los Angeles, CA

 

90045

(Address of principal executive offices)

 

(Zip Code)



Registrant's telephone number, including area code:

 

(310) 258-5000



 

(Former name or former address, if changed since last report)


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



ITEM 7.01

REGULATION FD DISCLOSURE.

On October 15, 2007, CompuMed, Inc. issued a press release today announcing the United States Patent and Trademark Office has issued the company a patent for an automated method and system to assess or monitor the extent or progression of joint-damaging diseases such as osteoarthritis and rheumatoid arthritis. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference."


ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS.


(d)  Exhibits


EXHIBIT

NUMBER

 

DESCRIPTION

 

 

 

99.1

 

Compumed, Inc. awarded US Patent for technology to monitor joint disease.




SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CompuMed, Inc.

 

 

(Registrant)

 

 

 

 Date: October 15, 2007

By:

/s/ Maurizio Vecchione

 

 

 

Maurizio Vecchione

 

 

Interim Chief Executive Officer